EDIT
Editas Medicine IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$415.88M
P/E Ratio
—
EPS
$-1.14
Beta
2.10
52W High
$4.54
52W Low
$1.66
50-Day MA
$2.92
200-Day MA
$2.67
Dividend Yield
—
Profit Margin
-281.60%
Forward P/E
—
PEG Ratio
0.00
About Editas Medicine Inc
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $38.69M |
| Gross Profit (TTM) | $-42.27M |
| EBITDA | $-85.19M |
| Operating Margin | -883.00% |
| Return on Equity | -326.10% |
| Return on Assets | -27.00% |
| Revenue/Share (TTM) | $0.42 |
| Book Value | $0.04 |
| Price-to-Book | 116.28 |
| Price-to-Sales (TTM) | 11.20 |
| EV/Revenue | 10.5 |
| EV/EBITDA | -1.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -39.20% |
| Shares Outstanding | $153.46M |
| Float | $97.73M |
| % Insiders | 0.18% |
| % Institutions | 49.23% |
Historical Volatility
HV 10-Day
151.20%
HV 20-Day
113.51%
HV 30-Day
104.97%
HV 60-Day
87.88%
HV Rank
84.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($5.78 target)
7
Buy5
Hold2
Strong SellMore HEALTHCARE Stocks
Data last updated: 6/6/2026